Antibody Botox Drugs Research 
The Pharma Data
SEPTEMBER 8, 2021
–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine –These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum.
The Pharma Data
SEPTEMBER 10, 2021
“Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.” BOTOX ® Abstracts. BOTOX ® (onabotulinumtoxinA) Important Information.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 7, 2021
” Researchers will present data from several studies on migraine, including new findings on atogepant, AbbVie’s investigational preventive treatment of migraine in adults who meet criteria for episodic migraine as well as results evaluating the efficacy and safety of BOTOX ® (onabotulinumtoxinA) and UBRELVY ® (ubrogepant).
XTalks
AUGUST 2, 2023
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. billion in 2022.
The Pharma Data
AUGUST 1, 2021
Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 On a GAAP basis, research and development expense was 12.9 to $6.14; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.37 percent on a reported basis, or 29.6
The Pharma Data
APRIL 30, 2021
Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 On a GAAP basis, research and development expense was 13.7 Global net revenues from the aesthetics portfolio were $1.141 billion , an increase of 34.9 percent of net revenues.
Expert insights. Personalized for you.
52 
Let's personalize your content